transact costar

Friday, February 3, 2012

Venture Capital Firms in New York: Chase Your Dreams | Forex ...

Starting a business is not as easy as it looks. If you have the money support your ideas you can start up your businesses. Unfortunately not all of us have enough money. There are times that even bank loans refuse to provide funds for your business.

Fortunately there are venture capital firms are willing to raise the stakes and take the risk. Relying on outside investors is natural for business, even established seek venture capital funds for added capital. Finding a private equity firm is not difficult, especially if you?re in New York. In the city that never sleeps, money continues to roll even though the CEO is asleep.

JP Morgan Chase and Co. is one of the leading venture capital films in New York. It?s a firm that has $1.6 trillion in assets and operates in 50 countries. Its headquarters is located in New York wile its commercial banking headquarters is in Chicago.

New York is considered one of the hubs of business so it?s natural that you will find the leading private equity firms there. Most venture capitalists are interested in high technology but JP Morgan and Chase leans toward a sector that they experienced with: banking and financial services.

Chase and Co.

The company has a long history dated back to 1799. Six companies merged in 2004 to form JP Morgan Chase and Co. These companies are Chase Manhattan, JP Morgan, Chemical Banking Corp., Bank One, National Bank of Detroit, First Chicago and Manufacturers Hanover.

JP Morgan portfolio includes businesses in investment and Private banking, private client and worldwide security services, asset management and one equity partners. Chase invests in consumer and banking businesses in the United States. This includes credit cards, home finance and equity loans, auto finance, small business, insurance and education finance. Their commercial banking business focuses on middle market, equipment leasing, corporate business credit, and commercial real estate.

Apart from engaging in large markets they also invest in communities to strengthen economic development. The Community Development Group provides capital, access to its resources and network. They serve low to moderate income communities, individuals and families, and small businesses owned by minority and women.

They help these communities by providing services through credit, banking, technical assistance, mortgages and advisory services. They also provide funds for non profit businesses located in these communities.

The best part about the firms is that they are willing to invest in a diversity of partners. They are operating in more than 50 countries which mean they don?t just focus in positive returns but also a diverse investment portfolio for the benefit of its clients.

The firm is a big company that caters a wide demographic. They are focused not just on big start up companies but also small ones. Naturally, getting your business plan approved may not be easy. The firm poses a promise but that is not a guarantee that your business will be approved with a check. It?s best to select a firm that matches the objectives and goals of your company.

There are many venture capital firms in New York and JP Morgan is one of them. As a leading global financial firm these gives them a cut above the rest. Seeking out outside investors for seed or growth capital is going to be essential for any business.

Read Recent Articles by the same Author about Garden Furniture

PFT: McNabb doesn't sound ready to retire

Getty Images

In public, the Colts have been mostly tight lipped about Peyton Manning?s future since the season ended. Owner Jim Irsay initially insisted Manning would remain a Colt if healthy, though he?s gradually backed off that stance. Ultimately, Irsay has made no commitment either way while being as evasive about Manning?s 2012 whereabouts as humanly possible.

Newly hired offensive coordinator Bruce Arians was more forthcoming about Manning than Irsay has ever been in an item posted on the Colts? website Wednesday. When reading Arians? quotes, keep in mind that he was the Colts? quarterbacks coach from 1998 through 2000 and is returning to the organization after 11 years away.

?It?s like deja vu like in 1998, starting off with a new general manager, a new head coach, and a new quarterback,? said Arians. ?It was so exciting to watch that process grow into what it has become.?

Arians seems to be of the impression that the Colts are in a full, top-to-bottom rebuild. And that rebuild includes a quarterback change. Later in the Colts.com article, Arian backtracked a bit.

?Hopefully we have Peyton (Manning) back ? I have my fingers crossed ? but possibly starting with another young one, it?s really exciting,? Arians said.

It?s no secret by now that the Colts expect to move on from Manning. Arians knows it; he?s openly ?excited? about it. According to NFL Network?s Jason La Canfora, new G.M. Ryan Grigson knew about it ?weeks ago.?

Arians is just the only one who has come close to saying it.

Source: http://profootballtalk.nbcsports.com/2012/02/01/mcnabb-doesnt-sound-ready-to-retire/related/

jason segel turducken power rangers jungle fury power rangers jungle fury ufc 139 fight card houston nutt houston nutt

Thursday, February 2, 2012

Amazon makes India debut with Junglee.com (AP)

MUMBAI, India ? Amazon.com is coming to India, with the Thursday launch of Junglee.com, a watered-down version of its global shopping portal.

Junglee.com offers 12 million products from more than 14,000 Indian and global brands, the Seattle-based company said in a statement Thursday.

The site allows shoppers to compare prices, but most actual purchases must be made through a network of third-party retailers.

Indians will be able to buy shoes from Reebok, computer gadgets from Microsoft India, clothes from Fabindia and luxury leather handbags from Hidesign.

Some items ? including the Kindle ? are sold by Amazon.com directly, but will be subject to steep international shipping and customs fees.

"We are excited to give customers in India a single online starting point where they can shop a wide selection of products sold by local and global retailers, and make informed purchasing decisions," Amit Agarwal, vice president of Amazon.com, said in a statement.

Internet penetration in India remains low, but online retailing is a fast-growing business.

India's e-commerce market is expected to grow from $10 billion in 2011 to $200 billion by 2020, as the number of Indians with Internet access expands eightfold, to 800 million, according to Technopak Advisors, a consulting company based in New Delhi.

Amazon's arrival will ratchet up competition among local heavyweights such as FlipKart.com, which was started by two former Amazon employees, and offers speedy, cash-on-delivery service for a range of products, including books, electronics, music and home appliances.

Source: http://us.rd.yahoo.com/dailynews/rss/tech/*http%3A//news.yahoo.com/s/ap/20120202/ap_on_hi_te/as_india_amazon

morgan freeman jon huntsman bit coin huntsman episodes christopher plummer w.e.

Crafting ideas to follow along with Upward After having a Business ...

Within this time period, it really is not sufficient in order to turn to a person making a display. Unless you follow-up a minimum of Seven periods, you happen to be squandering your period, in addition to theirs. The more period you put straight into getting to know your own customers, the greater your own connection is going to be. boca raton seo, cold sores or low carb diet plan

Because of that, you have to follow-up following a display, a minimum of Seven periods, and infrequently more time. Right here you will find a number of strategies to follow way up which will be guaranteed to impress any individual.

A single. The initial follow-up needs to be a hand created notice, saying thanks to these people for their period. Use a great greeting card, printed together with your company logo, if you?d like, or just a straightforward ?Thank You? greeting card accessible wherever.

2. Second, find a number of ?Cheese Straws? at the specialized store, and also deliver it which has a notice saying: ?Grasping at straws to discover the ideal solution to?(will include a problem you can fix on their behalf)? We could support! This is not merely a expertly worded indication of your display, yet some thing for them to style and remember anyone simply by.

Three or more. Rolodex cards are wonderful pointers: will include a be aware that claims: ?We are always when you need it if you want us!Inch Be sure your own rolodex greeting card has got the small tab at the very top with either your reputation, or even the biggest advantage of utilizing your providers: this will make it differentiate themselves from the others cards inside the document.

Several. Next, deliver a handbag regarding stovetop popcorn which has a notice saying: ?Just popping in to advise anyone that individuals can?. Inch (refer to one benefit of employing your services or perhaps products).

Your five. A new coffee mug published together with your company logo, and also full of a number of espresso boxes or a cookie could possibly be up coming: this may advise these people of your check out should they appreciate their espresso.

6. A new seedling bundle with this communication: ?We would love to help you expand your business? is yet another initial proven fact that may leave a great perception.

Seven. Chocolate business card printing might be a yummy indication of your providers. That one can be a bit more expensive, yet definitely worth the cost. You?ll want to buy a denture together with your company logo, yet it?s single period cost that may purchase from you often around. The dark chocolate business card printing are a good conversation beginner, and another that may independent you from your competition.

These are simply a couple of suggestions: there are numerous more ways to maintain your title facing your own potential customers.

And also to keep track of what you do, produce a directory for every display as well as set your follow-ups before you even see your display.

You are now on your journey to good results: dolphins, good luck the next display!

Source: http://www.cordsen.info/crafting-ideas-to-follow-along-with-upward-after-having-a-business-presentation/

beyonce dance for you video beyonce dance for you video asu football asu football arkansas lsu storage wars storage wars

Wednesday, February 1, 2012

Research from the 2012 Genitourinary Cancers Symposium highlights new treatments, compares existing therapies for prostate cancer

Public release date: 31-Jan-2012
[ | E-mail |

Share ]

Contact: Susie Tappouni
susie.tappouni@asco.org
571-483-1355
American Society of Clinical Oncology

ALEXANDRIA, Va. Research on promising new therapies and data on the relative benefits of established treatments for prostate cancer were released today, in advance of the fourth annual Genitourinary Cancers Symposium, being held February 2-4, 2012, at the San Francisco Marriott Marquis in San Francisco, Calif.

The results of five studies were highlighted in a media presscast (press briefing via live webcast):

1) Vigorous Exercise Linked to Expression of Certain Genes in Early-Stage Prostate Cancer: A study shows that men with early-stage prostate cancer who exercise vigorously at least three hours a week have more than 180 genes that are expressed differently in the prostate than those who did not exercise as intensively. These genes include known tumor suppressor genes and DNA repair pathways, suggesting a number of potential mechanisms by which vigorous exercise may help delay cancer progression, as prior studies have shown.

2) IMRT Better Than Conformal Radiation Therapy for Reducing Prostate Cancer Recurrence and Side Effects, May Also Be Superior to Proton Beam Therapy: A large comparative effectiveness study shows that men with localized prostate cancer who are treated with intensity modulated radiation therapy (IMRT) are less likely to experience cancer recurrence or significant side effects from treatment than those who receive conventional conformal radiation therapy (CRT). The analysis also found that proton beam therapy, a newer and more costly form of radiation treatment, did not significantly improve outcomes compared to IMRT.

3) External Beam Radiation Leads to Most Side Effects, Highest Costs of Three Common Prostate Cancer Treatments: An analysis of more than 100,000 prostate cancer patients shows that treatment with external beam radiation therapy (EBRT) resulted in higher long-term toxicities and treatment-related costs than prostatectomy and brachytherapy, two other common treatments for the disease.

4) Novel Investigational Drug Targeting Bone Metastases Improves Survival for Metastatic Prostate Cancer: A randomized, phase III trial shows that a new radiation-emitting agent aimed at treating bone metastases both improved survival and delayed cancer-related bone problems in men with castration-resistant prostate cancer (CRPC). The agent, radium-223 chloride, is the first alpha particle emitting agent targeting bone metastases shown to improve survival in metastatic CRPC.

5) Study Shows New Targeted Drug Improves Overall Survival in Metastatic Prostate Cancer: An international, randomized phase III trial shows for the first time that an investigational oral drug that halts androgen signaling significantly improves overall survival in patients with metastatic castration-resistant prostate cancer.

"It's gratifying that two of the presentations reported today provide us with new options to improve survival for patients with advanced castrate-resistant prostate cancer, an especially difficult disease with few effective treatments," said Nicholas J. Vogelzang, MD, Chair and Medical Director of the Developmental Therapeutics Committee of US Oncology, who moderated today's presscast. "Just as importantly, today's studies will help guide our use of several established treatments in the field, ensuring that more patients receive the best possible therapies while avoiding unnecessary side effects and costs."

Genitourinary cancers include those of the prostate, kidney, bladder and testis, as well as less common cancers such as those of the penis, ureters and other urinary organs. In 2012, more than 390,000 people in the United States are expected to be diagnosed with genitourinary cancers, with more than an estimated 58,000 deaths. The most common genitourinary cancer is prostate cancer, which according to estimates, will be diagnosed in more than 241,000 men in the United States in 2012, and claim more than 28,000 lives.*
###

The Genitourinary Cancers Symposium is co-sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO).

To view the full release click the following link: http://www.asco.org/ASCOv2/Department%20Content/Communications/Downloads/GU%202012%20Research%20Release%20FINAL.pdf

Information for Media: http://www.asco.org/GUpresskit

Relevant Links From Cancer.Net, the oncologist-approved cancer information website from the American Society of Clinical Oncology:

1) Guide to Prostate Cancer

2) Understanding Radiation Therapy

3) Managing the Cost of Cancer Care

4) Survivorship

5) Late Effects

6) Bone Health During Cancer Treatment

7) Physical Activity and Cancer Risk

An interactive history of cancer research advances, including those in prostate cancer, can be found at www.cancerprogress.net.

Cancer Facts & Figures 2012. Atlanta, GA; American Cancer Society: 2012.

ATTRIBUTION TO THE 2012 GENITOURINARY CANCERS SYMPOSIUM IS REQUESTED IN ALL NEWS COVERAGE.

[ | E-mail | Share ]
?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.*

Research from the 2012 Genitourinary Cancers Symposium highlights new treatments, compares existing therapies for prostate cancer Public release date: 31-Jan-2012
[ | E-mail | Share ]
Contact: Susie Tappouni
susie.tappouni@asco.org
571-483-1355
American Society of Clinical Oncology

ALEXANDRIA, Va. Research on promising new therapies and data on the relative benefits of established treatments for prostate cancer were released today, in advance of the fourth annual Genitourinary Cancers Symposium, being held February 2-4, 2012, at the San Francisco Marriott Marquis in San Francisco, Calif.

The results of five studies were highlighted in a media presscast (press briefing via live webcast):

1) Vigorous Exercise Linked to Expression of Certain Genes in Early-Stage Prostate Cancer: A study shows that men with early-stage prostate cancer who exercise vigorously at least three hours a week have more than 180 genes that are expressed differently in the prostate than those who did not exercise as intensively. These genes include known tumor suppressor genes and DNA repair pathways, suggesting a number of potential mechanisms by which vigorous exercise may help delay cancer progression, as prior studies have shown.

2) IMRT Better Than Conformal Radiation Therapy for Reducing Prostate Cancer Recurrence and Side Effects, May Also Be Superior to Proton Beam Therapy: A large comparative effectiveness study shows that men with localized prostate cancer who are treated with intensity modulated radiation therapy (IMRT) are less likely to experience cancer recurrence or significant side effects from treatment than those who receive conventional conformal radiation therapy (CRT). The analysis also found that proton beam therapy, a newer and more costly form of radiation treatment, did not significantly improve outcomes compared to IMRT.

3) External Beam Radiation Leads to Most Side Effects, Highest Costs of Three Common Prostate Cancer Treatments: An analysis of more than 100,000 prostate cancer patients shows that treatment with external beam radiation therapy (EBRT) resulted in higher long-term toxicities and treatment-related costs than prostatectomy and brachytherapy, two other common treatments for the disease.

4) Novel Investigational Drug Targeting Bone Metastases Improves Survival for Metastatic Prostate Cancer: A randomized, phase III trial shows that a new radiation-emitting agent aimed at treating bone metastases both improved survival and delayed cancer-related bone problems in men with castration-resistant prostate cancer (CRPC). The agent, radium-223 chloride, is the first alpha particle emitting agent targeting bone metastases shown to improve survival in metastatic CRPC.

5) Study Shows New Targeted Drug Improves Overall Survival in Metastatic Prostate Cancer: An international, randomized phase III trial shows for the first time that an investigational oral drug that halts androgen signaling significantly improves overall survival in patients with metastatic castration-resistant prostate cancer.

"It's gratifying that two of the presentations reported today provide us with new options to improve survival for patients with advanced castrate-resistant prostate cancer, an especially difficult disease with few effective treatments," said Nicholas J. Vogelzang, MD, Chair and Medical Director of the Developmental Therapeutics Committee of US Oncology, who moderated today's presscast. "Just as importantly, today's studies will help guide our use of several established treatments in the field, ensuring that more patients receive the best possible therapies while avoiding unnecessary side effects and costs."

Genitourinary cancers include those of the prostate, kidney, bladder and testis, as well as less common cancers such as those of the penis, ureters and other urinary organs. In 2012, more than 390,000 people in the United States are expected to be diagnosed with genitourinary cancers, with more than an estimated 58,000 deaths. The most common genitourinary cancer is prostate cancer, which according to estimates, will be diagnosed in more than 241,000 men in the United States in 2012, and claim more than 28,000 lives.*
###

The Genitourinary Cancers Symposium is co-sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO).

To view the full release click the following link: http://www.asco.org/ASCOv2/Department%20Content/Communications/Downloads/GU%202012%20Research%20Release%20FINAL.pdf

Information for Media: http://www.asco.org/GUpresskit

Relevant Links From Cancer.Net, the oncologist-approved cancer information website from the American Society of Clinical Oncology:

1) Guide to Prostate Cancer

2) Understanding Radiation Therapy

3) Managing the Cost of Cancer Care

4) Survivorship

5) Late Effects

6) Bone Health During Cancer Treatment

7) Physical Activity and Cancer Risk

An interactive history of cancer research advances, including those in prostate cancer, can be found at www.cancerprogress.net.

Cancer Facts & Figures 2012. Atlanta, GA; American Cancer Society: 2012.

ATTRIBUTION TO THE 2012 GENITOURINARY CANCERS SYMPOSIUM IS REQUESTED IN ALL NEWS COVERAGE.

[ | E-mail | Share ]
?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.*

Source: http://www.eurekalert.org/pub_releases/2012-01/asoc-sbf013112.php
miracle on 34th street santa tracker patrice oneal monkey bread letter from santa sweet potato pie sweet potato pie